SEC Filings

Form 10-K
XBIOTECH INC. filed this Form 10-K on 03/16/2017
Document Outline
Entire Document (2333.9 KB)
Subdocument 1 - 10-K - FORM 10-K
Page 1 - UNITED STATES
Page 2 - Documents incorporated by reference:
Page 3 - CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
Page 4 - You should also read the matters described in the Risk Factors and the other cautionary statements m
Page 5 - Overview
Page 6 - Staphylococcus aureus
Page 7 - A Background on Therapeutic Antibodies
Page 8 - Fundamental Science of True Human Antibodies
Page 9 - Industry Context
Page 10 - Our Strategy
Page 11 - Product Pipeline
Page 12 - The Lancet Oncology
Page 13 - Phase I/II Study for Staphylococcus aureus
Page 14 - Intellectual Property
Page 15 - G. Arthritis Treatment.
Page 16 - Employees
Page 17 - Risks Related to our Financial Condition and Capital Requirements
Page 18 - Raising additional capital may cause dilution to our existing shareholders, restrict our operations
Page 19 - Risks Related to Our Business
Page 20 - N/A
Page 21 - New laws or regulations may be promulgated or modified in the United States, in Europe, or other jur
Page 22 - Because the results of earlier clinical trials are not necessarily predictive of future results, pro
Page 23 - The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengt
Page 24 - Our lead product candidate or our other product candidates may cause undesirable side effects or hav
Page 25 - Even if our lead product candidate or our other product candidates receive regulatory approval, they
Page 26 - Failure to obtain regulatory approval in foreign jurisdictions would prevent our lead product candid
Page 27 - We have never marketed a drug before, and if we are unable to establish an effective sales force and
Page 28 - Our research programs may not succeed
Page 29 - Even an effective drug candidate might not be commercially successful.
Page 30 - Product liability lawsuits against us could cause us to incur substantial liabilities and to limit c
Page 31 - We are highly dependent on our Chief Executive Officer.
Page 32 - Business disruptions could seriously harm our future revenues and financial condition and increase o
Page 33 - Intellectual property rights do not necessarily address all potential threats to any competitive adv
Page 34 - We may need to license intellectual property from third parties, and such licenses may not be availa
Page 35 - Insiders continue to have substantial control over our company since our initial public offering in
Page 36 - Provisions in our charter documents under Canadian law could make an acquisition of us, which may be
Page 37 - Future sales, or the possibility of future sales, of a substantial number of our common stock could
Page 38 - N/A
Page 39 - Market Information
Page 40 - N/A
Page 41 - You should read the following discussion and analysis of our financial condition and results of oper
Page 42 - Revenues
Page 43 - Critical Accounting Policies
Page 44 - Results of Operations
Page 45 - General and Administrative
Page 46 - Liquidity and Capital Resources
Page 47 - Contractual Obligations and Commitments
Page 48 - Index to Financial Statements
Page 49 - Report of Independent Registered Public Accounting Firm
Page 50 - XBiotech Inc.
Page 51 - XBiotech Inc.
Page 52 - XBiotech Inc.
Page 53 - XBiotech Inc.
Page 54 - XBiotech Inc.
Page 55 - XBiotech Inc.
Page 56 - Research and Development Costs
Page 57 - Cash and Cash Equivalents
Page 58 - Property and Equipment
Page 59 - Net Loss per Share
Page 60 - 4. Accrued Expenses
Page 61 - 6. Common Stock Options
Page 62 - 7. Net Loss Per Share
Page 63 - N/A
Page 64 - 9. Related-Party Transactions
Page 65 - Management's Evaluation of our Disclosure Controls and Procedures
Page 66 - PART IV
Page 67 - SIGNATURES
Page 68 - EXHIBIT INDEX
Page 69 - N/A
Subdocument 2 - EX-21.1 - EXHIBIT 21.1
Page 1 - Exhibit 21.1
Subdocument 3 - EX-23.1 - EXHIBIT 23.1
Page 1 - Exhibit 23.1
Subdocument 4 - EX-31.1 - EXHIBIT 31.1
Page 1 - Exhibit 31.1
Subdocument 5 - EX-31.2 - EXHIBIT 31.2
Page 1 - Exhibit 31.2
Subdocument 6 - EX-32.1 - EXHIBIT 32.1
Page 1 - Exhibit 32.1
Subdocument 7 - EX-32.2 - EXHIBIT 32.2
Page 1 - Exhibit 32.2
XBRL Item - EX-101.INS - XBRL INSTANCE FILE (What's this?)
XBRL Item - EX-101.SCH - XBRL SCHEMA FILE (What's this?)
XBRL Item - EX-101.CAL - XBRL CALCULATION FILE (What's this?)
XBRL Item - EX-101.DEF - XBRL DEFINITION FILE (What's this?)
XBRL Item - EX-101.LAB - XBRL LABEL FILE (What's this?)
XBRL Item - EX-101.PRE - XBRL PRESENTATION FILE (What's this?)
XBRL Viewer